Riccardo Perfetti Sells 2,560 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) Stock

Applied Therapeutics, Inc. (NASDAQ:APLT) insider Riccardo Perfetti sold 2,560 shares of the business’s stock in a transaction dated Friday, April 30th. The stock was sold at an average price of $18.39, for a total transaction of $47,078.40. Following the sale, the insider now directly owns 1,640 shares in the company, valued at approximately $30,159.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Riccardo Perfetti also recently made the following trade(s):

  • On Wednesday, April 28th, Riccardo Perfetti sold 1,640 shares of Applied Therapeutics stock. The stock was sold at an average price of $18.44, for a total transaction of $30,241.60.
  • On Wednesday, April 14th, Riccardo Perfetti sold 200 shares of Applied Therapeutics stock. The stock was sold at an average price of $17.11, for a total transaction of $3,422.00.
  • On Tuesday, March 30th, Riccardo Perfetti sold 460 shares of Applied Therapeutics stock. The stock was sold at an average price of $18.43, for a total transaction of $8,477.80.
  • On Friday, March 26th, Riccardo Perfetti sold 465 shares of Applied Therapeutics stock. The stock was sold at an average price of $19.68, for a total transaction of $9,151.20.
  • On Monday, March 15th, Riccardo Perfetti sold 465 shares of Applied Therapeutics stock. The stock was sold at an average price of $19.61, for a total transaction of $9,118.65.
  • On Friday, March 12th, Riccardo Perfetti sold 465 shares of Applied Therapeutics stock. The stock was sold at an average price of $19.38, for a total transaction of $9,011.70.
  • On Thursday, February 25th, Riccardo Perfetti sold 1,295 shares of Applied Therapeutics stock. The stock was sold at an average price of $23.20, for a total transaction of $30,044.00.
  • On Tuesday, February 23rd, Riccardo Perfetti sold 465 shares of Applied Therapeutics stock. The stock was sold at an average price of $21.84, for a total transaction of $10,155.60.
  • On Wednesday, February 3rd, Riccardo Perfetti sold 1,295 shares of Applied Therapeutics stock. The stock was sold at an average price of $26.79, for a total transaction of $34,693.05.
  • On Monday, February 1st, Riccardo Perfetti sold 1,460 shares of Applied Therapeutics stock. The stock was sold at an average price of $25.30, for a total transaction of $36,938.00.

APLT opened at $18.52 on Monday. Applied Therapeutics, Inc. has a 52-week low of $13.58 and a 52-week high of $51.99. The company has a 50 day moving average of $18.19 and a two-hundred day moving average of $20.62. The company has a market cap of $481.72 million, a P/E ratio of -3.89 and a beta of 1.27.

Applied Therapeutics (NASDAQ:APLT) last released its quarterly earnings data on Wednesday, March 17th. The company reported ($1.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.25) by $0.19. As a group, equities research analysts anticipate that Applied Therapeutics, Inc. will post -4.51 EPS for the current year.

Several hedge funds have recently made changes to their positions in the company. Orbimed Advisors LLC boosted its stake in shares of Applied Therapeutics by 14.6% in the fourth quarter. Orbimed Advisors LLC now owns 1,771,831 shares of the company’s stock valued at $38,998,000 after purchasing an additional 225,144 shares during the period. BlackRock Inc. boosted its stake in shares of Applied Therapeutics by 27.6% in the fourth quarter. BlackRock Inc. now owns 1,056,160 shares of the company’s stock valued at $23,246,000 after purchasing an additional 228,221 shares during the period. Emerald Mutual Fund Advisers Trust boosted its stake in shares of Applied Therapeutics by 19.4% in the first quarter. Emerald Mutual Fund Advisers Trust now owns 644,572 shares of the company’s stock valued at $12,089,000 after purchasing an additional 104,932 shares during the period. Emerald Advisers LLC boosted its stake in shares of Applied Therapeutics by 7.5% in the first quarter. Emerald Advisers LLC now owns 554,279 shares of the company’s stock valued at $10,396,000 after purchasing an additional 38,555 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in shares of Applied Therapeutics by 5.2% in the fourth quarter. Bank of New York Mellon Corp now owns 58,672 shares of the company’s stock valued at $1,291,000 after purchasing an additional 2,911 shares during the period. Institutional investors and hedge funds own 54.25% of the company’s stock.

A number of equities analysts have issued reports on the stock. Robert W. Baird restated a “buy” rating and set a $35.00 target price on shares of Applied Therapeutics in a research report on Sunday, March 21st. Zacks Investment Research lowered shares of Applied Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, March 24th.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG.

See Also: No Load Funds

Insider Buying and Selling by Quarter for Applied Therapeutics (NASDAQ:APLT)

Receive News & Ratings for Applied Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.